Project Grant R21CA282561
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$219K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Tyler, TX 75708, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,829.00 to the University of Washington to develop a novel framework for guiding re-irradiation treatments. The key objectives are: Quantifying the evolution of normal tissue damage and recovery after radiation therapy using imaging biomarkers in the liver and lungs. This will help characterize a patient-specific normal tissue recovery parameter. Exploring the feasibility of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $375,134 to the University of Colorado-Denver to investigate a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can tighten healthy tissues, thereby limiting nanoparticle deposition and associated toxicity, while enabling improved delivery to tumors. The research...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research at the University of North Carolina at Chapel Hill to investigate the impact of NRF2 signaling on lung squamous cell carcinoma (LUSC) development. The project will utilize a novel genetically-engineered mouse model to assess how NRF2 activation affects LUSC incidence, tumor characteristics, and the tumor microenvironment. The total funding of $158,365 will be...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $662,516 aims to investigate how fractionated radiation affects the tumor microenvironment to enhance drug delivery and improve the safety and efficacy of chemoradiotherapy for locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The key research objectives include: 1) Quantifying how local radiation reshapes the tumor microenvironment to influence...
This $749,474 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Beth Israel Deaconess Medical Center, Inc. (Bidmc) supports scientific research to elucidate the underlying processes of failed resolution of inflammation initiated by environmental chemicals. The study aims to profile lipid autacoid mediators and cytokines to evaluate pro-resolving lipid mediators as interventional targets in chemical-induced cancer. The research will also investigate...
The federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is focused on developing noninvasive imaging and blood-based biomarkers to improve prediction of immunotherapy response and clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC). The $1,820,020 award, which runs from May 2024 to April 2029, will support research to: (1) create knowledge-guided radiomics and deep...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $696,569 to New York University School of Medicine to conduct research aimed at developing a novel therapeutic strategy for targeting lung cancer. The key goals of the 5-year project are to: 1) characterize the impact of the protein lipocalin 2 (LCN2) on the tumor microenvironment, 2) develop antibody-based therapies that interfere with LCN2 function, and 3) determine the...
This federal Project Grant award, valued at $696,447.00 and made by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development and evaluation of a novel approach to targeted alpha particle therapy for mesothelioma, a difficult-to-treat cancer. The primary focus is on targeting a tumor-selective CD46 epitope expressed across mesothelioma subtypes, including the sarcomatoid subtype which lacks effective treatments. The work will leverage a...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $566,523 to support research on identifying interception targets in persistent lung premalignant lesions that are at risk of progressing to lung cancer. The research aims to leverage clinical trial data and human-relevant mechanistic studies to determine how prevention agents can target the persistence pathways underlying the most high-risk...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to SRI International provides $401,125 in funding to quantify the association between genetic factors and radiation sensitivity in cancer patients. The research aims to identify germline genetic variants and gene expression patterns that contribute to individual differences in radiation response. The goal is to develop a predictive screening platform to optimize radiation dosing and mitigate...